# Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

October 2, 2024

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024.

**Fireside Chat Presentation Details:**

| | |
|---|---|
| **Date:** | Monday, October 7, 2024 |
| **Time:** | 11:40 am Eastern Time |
| **Webcast:** | Register here |

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

**About Xenon Pharmaceuticals Inc.**

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, our lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

**Contacts:**
*For Investors:*
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

*For Media:*
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

Source: Xenon Pharmaceuticals Inc.